UBS downgrades Novo Nordisk, cites 'rapidly deteriorating growth' in GLP-1 market
-
最新报道：UBS downgraded Novo Nordisk from "buy" to "neutral," citing slowing growth prospects for its GLP-1 diabetes and obesity drugs. The bank cut its price target to $150 from $170, noting intensifying competition in the weight-loss drug market from rivals like Eli Lilly. Novo Nordisk shares fell 3% following the downgrade, though the company maintains strong sales from blockbuster drugs Ozempic and Wegovy. Analysts warn pricing pressures may emerge as more competitors enter the lucrative obesity treatment sector.
下一篇
Axal Partners with MoonPay to Launch Virtual Bank Accounts with Onchain Yield Through Axal Yield
- AXAL partners with MoonPay to introduce virtual bank accounts featuring on-chain yield via...
24小时热点
热点专题
413124